Ainos Reveals $600K Upfront and 25% Sublicensing Cut in VELDONA Deal
AIMD is trading near its 52-week low of $1.25 (5.6% above the low).
Summary
Ainos disclosed the financial structure of its VELDONA license agreement with BioPhoenix, including a $600,000 initial fee payable within 15 business days, a 25% share of net sublicensing revenue, and a separate first-sublicense fee. The partner will fund and execute clinical and regulatory work for Sjögren's disease and thrombocytopenia, reducing Ainos' capital needs. The framework could reach $10 million across initial and additional indication licenses, with further upside from sublicensing and supply deals. This follows the September 24 announcement and adds concrete near-term cash and long-term participation terms. The company retains platform ownership and can pursue direct licenses for other indications.
At the time of this announcement, AIMD was trading at $1.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.25 to $4.44. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.